COMPANY
Veradermics
Funding and NIH signals
- SEC Form D raise Raised $30M (Form D filed May 15, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001827635-26-000020 (May 15, 2026)
Evidence (2 events)
- May 15, 2026 · SEC Form D 0001827635-26-000020
Name of Issuer: Veradermics, Inc; CIK: 1827635; Address: New Haven, CT; Submission type: D; Filing date: 2026-05-15; Industry Group: Other Health Care; Date of First Sale: 2026-05-01; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 29999997; Total Amount Sold: 29999997; Federal exemptions: 06b - Oct 28, 2025 · SEC Form D 0001231919-25-000361
Name of Issuer: Veradermics, Inc; CIK: 1827635; Address: New Haven, CT; Submission type: D; Filing date: 2025-10-28; Industry Group: Other Health Care; Date of First Sale: 2025-10-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 149999978; Total Amount Sold: 134999978; Federal exemptions: 06b
- May 15, 2026 · SEC Form D 0001827635-26-000020
Timeline
- Trial start Phase 3: Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) source ↗
- Trial start Phase 3: Safety and Efficacy of VDPHL01 in Males With AGA source ↗
- Trial start Phase 2/Phase 3: Efficacy and Safety of VDPHL01 in Males With AGA source ↗
- Trial start Phase 2: Safety and Efficacy of VDPHL01 in Males and Females With AGA source ↗
- Trial start Phase 2: Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts source ↗
Upcoming milestones
- 2026-12 (ESTIMATED) · Phase 3 · Safety and Efficacy of VDPHL01 in Males With AGA · NCT06972264
- 2027-06 (ESTIMATED) · Phase 3 · Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) · NCT07146022
Clinical trials (lead sponsor) 5
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07146022 | Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | Phase 3 | Active, not recruiting | Jul 25, 2025 | 2027-06 (estimated) |
| NCT06972264 | Safety and Efficacy of VDPHL01 in Males With AGA | Phase 3 | Active, not recruiting | Mar 11, 2025 | 2026-12 (estimated) |
| NCT06724614 | Efficacy and Safety of VDPHL01 in Males With AGA | Phase 2/Phase 3 | Active, not recruiting | Nov 6, 2024 | 2026-02 (estimated) |
| NCT06527365 | Safety and Efficacy of VDPHL01 in Males and Females With AGA | Phase 2 | Active, not recruiting | Jul 8, 2024 | 2026-08 (estimated) |
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | Phase 2 | Completed | Feb 28, 2023 | Feb 25, 2025 (actual) |